Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397988 | 0.83 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL25387611 | 0.78 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL5576828 | 0.72 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL25389668 | 0.72 | KDM4E (0.40) | KDM4E | |
| SCHEMBL1612197 | 0.72 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL6365760 | 0.71 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL25968172 | 0.71 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL7155978 | 0.70 | KDM4E (0.38) | KDM4E | |
| SCHEMBL10276803 | 0.70 | TYMP (0.44) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL22381973 | 0.70 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086813-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086813-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | REL, RELA, NFKB1 | KDM4E 2520/4885TAS1R3 4693/4885TAS1R1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.